COMMUNIQUÉS West-GlobeNewswire

Med X Holdings Announces Official Name Change to Dazed Inc. and New Ticker Symbol "DAZD"
22/07/2026
Welcome to Dazed Inc. Austin, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Med X Holdings Announces Official Name Change to Dazed Inc. and New Ticker Symbol "DAZD" AUSTIN, Texas – July 21, 2026 – Med X [...]
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
22/07/2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare [...]
CMR Surgical and NVIDIA showcase future of intelligent surgery with Versius Plus™ at SRS 2026
22/07/2026
CMR Surgical will demonstrate at SRS 2026, for the first time to a surgical audience, the potential for Versius Plus™ to leverage surgical data to help predict how a procedure may unfold. Built on NVIDIA Isaac for [...]
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
22/07/2026
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors
22/07/2026
MINNEAPOLIS, July 22, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA [...]
Specialized Manufacturing Capability Emerges as the New Competitive Advantage in the $23.2 Billion Global Biologics CDMO Market, Finds Alira Health
22/07/2026
Annual report examines how specialized manufacturing capabilities, investment, and M&A are reshaping the global biologics contract manufacturing landscape FRAMINGHAM, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Alira [...]
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
22/07/2026
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with [...]
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
22/07/2026
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
22/07/2026
Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and [...]
BioCryst to Report Second Quarter 2026 Financial Results on August 5
22/07/2026
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5 [...]
Acentra Health Appoints Sreedevi Hegde as Senior Vice President – India Country Head
22/07/2026
Seasoned global business leader to drive the growth of Acentra Health's India organization and accelerate the company's transformation journey MCLEAN, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology [...]
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
22/07/2026
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin [...]
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close [...]
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
22/07/2026
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) [...]
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
22/07/2026
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
uniQure to Announce Second Quarter 2026 Financial Results
22/07/2026
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing [...]
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
22/07/2026
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose- [...]
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, [...]

Pages